Author:
Damane Botle Precious,Maebele Lorraine Tshegofatso,Makgoka Malose,Mokone Dikeledi Hendrika,Mulaudzi Thanyani Victor,Rotimi Solomon Oladapo,Dlamini Zodwa
Publisher
Springer Nature Switzerland
Reference91 articles.
1. Aloss, K., & Hamar, P. (2023). Recent preclinical and clinical Progress in liposomal doxorubicin. Pharmaceutics, 15, 893.
2. Arathoon, R., Briante, R., O’connor, A., Tan, C., Klein, P., Morgan, J., Ponath, P., Presta, L., Zhai, Q., Mohanty, S., & Zhang, P. (2021). 282 bispecific antibodies (BsAbs) targeting ABCB1/PgP and CD47 provide a multi-modal, tumor-specific approach to combat drug resistant cancers. Journal for ImmunoTherapy of Cancer, 9, A306–A306.
3. Arenas, E. J., Martínez-Sabadell, A., Rius Ruiz, I., Román Alonso, M., Escorihuela, M., Luque, A., Fajardo, C. A., Gros, A., Klein, C., & Arribas, J. (2021). Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nature Communications, 12, 1237.
4. Bagegni, N. A., Davis, A. A., Clifton, K. K., & Ademuyiwa, F. O. (2022). Targeted treatment for high-risk early-stage triple-negative breast cancer: Spotlight on Pembrolizumab. Breast Cancer (Dove Med Press), 14, 113–123.
5. Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., & Cui, J. (2020). Mechanisms of cancer resistance to immunotherapy. Frontiers in Oncology, 10, 1290.